Study Summary:
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184.
Patients who meet all eligibility criteria will be enrolled to receive treatment with LP-184 at a dose determined based on the available cohort at the time of each patient's enrollment. Patients will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity. Dose escalation is planned with minimum of 3 patient cohorts (starting at dose level 1). After selection of the maximum tolerated dose (MTD), additional patients will be enrolled at two dose levels, including the MTD, as determined by the Safety Review Committee, until at least 10 patients each are treated at each dose to determine the recommended phase 2 dose.
Contact Us
About This Trial:
For more information about this and other studies and to inquire about eligibility, please call 215-214-1515. or fill out this form.
Protocol:
23-1029 / IRB20-2016
Phase:
I
Investigator:
Anthony J. Olszanski
Disease(s):
Advanced Solid Tumor
ClinicalTrials.gov
Visit ClinicalTrials.gov for a full clinical trial description
Full Title
A Phase 1A Dose Escalation Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors.
For more information about this and other studies and to inquire about eligibility, please call 215-214-1515.